Scholars@Duke
Tyler Wildes

Tyler Wildes

House Staff
Pathology

Selected Publications

Chronic Lymphocytic Leukemia With Two B-Cell Populations of Discordant Light Chain Restrictions in Individual Patients: Parallel Development of Biclonal B-Cell Neoplasms or Clonal Evolution With Isotype Switch?

Journal Article Am J Clin Pathol · April 4, 2023 OBJECTIVES: To evaluate clinicopathologic characteristics of biclonal chronic lymphocytic leukemia (CLL). METHODS: Retrospectively analyze clinical data and pathologic features. RESULTS: Ten cases were identified in which flow cytometry demonstrated an abn ... Full text Link to item Cite

Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas

Other · March 31, 2023 <div>AbstractPurpose:<p>Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.</p>Experi ... Full text Cite

Figure S5 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>T cell-released soluble factors induce HSPC differentiation only after recognition of antigen-matched target cells.</p> ... Full text Cite

Figure S4 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>HSPC-derived DCs generated in vitro display DC phenotype and function.</p> ... Full text Cite

Figure S4 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>HSPC-derived DCs generated in vitro display DC phenotype and function.</p> ... Full text Cite

Figure S6, S7, and S8 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>T cell recognition of cognate antigen drives release of soluble factors including IFN-g and GM-CSF. T cell-released IFN-g and GM-CSF contribute to HSPC differentiation. Supernatant transfer with cytokine knockout T cells differentiates the ... Full text Cite

Figure S3 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>HSPCs proliferate and differentiate into antigen-presenting cells in the presence of T cell-released soluble factors.</p> ... Full text Cite

Figure S1 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>Intravenously administered HSPCs durably engraft in gliomas, supplant host immunity, and differentiate into antigen-presenting cells.</p> ... Full text Cite

Data from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <div>Abstract<p><b>Purpose:</b> Adoptive T-cell immunotherapy (ACT) has emerged as a viable therapeutic for peripheral and central nervous system (CNS) tumors. In peripheral cancers, optimal efficacy of ACT is reliant on den ... Full text Cite

Figure S2 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>IFN-g is upregulated in the brain tumor microenvironment during T cell immunotherapy and drives HSPC differentiation into CD11c+MHCII+ DCs.</p> ... Full text Cite

Figure S6, S7, and S8 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>T cell recognition of cognate antigen drives release of soluble factors including IFN-g and GM-CSF. T cell-released IFN-g and GM-CSF contribute to HSPC differentiation. Supernatant transfer with cytokine knockout T cells differentiates the ... Full text Cite

Figure S3 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>HSPCs proliferate and differentiate into antigen-presenting cells in the presence of T cell-released soluble factors.</p> ... Full text Cite

Figure S1 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>Intravenously administered HSPCs durably engraft in gliomas, supplant host immunity, and differentiate into antigen-presenting cells.</p> ... Full text Cite

Figure S5 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>T cell-released soluble factors induce HSPC differentiation only after recognition of antigen-matched target cells.</p> ... Full text Cite

Data from Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas

Other · March 31, 2023 <div>AbstractPurpose:<p>Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.</p>Experi ... Full text Cite

Figure S2 from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <p>IFN-g is upregulated in the brain tumor microenvironment during T cell immunotherapy and drives HSPC differentiation into CD11c+MHCII+ DCs.</p> ... Full text Cite

Data from Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma

Other · March 31, 2023 <div>Abstract<p><b>Purpose:</b> Adoptive T-cell immunotherapy (ACT) has emerged as a viable therapeutic for peripheral and central nervous system (CNS) tumors. In peripheral cancers, optimal efficacy of ACT is reliant on den ... Full text Cite

Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis.

Journal Article Journal for immunotherapy of cancer · February 2023 BackgroundGlioma-induced immune dysregulation of the hematopoietic system has been described in a limited number of studies. In this study, our group further demonstrates that gliomas interrupt the cellular differentiation programming and outcomes ... Full text Cite

Myelopoiesis during Solid Cancers and Strategies for Immunotherapy.

Journal Article Cells · April 2021 Our understanding of the relationship between the immune system and cancers has undergone significant discovery recently. Immunotherapy with T cell therapies and checkpoint blockade has meaningfully changed the oncology landscape. While remarkable clinical ... Full text Cite

Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.

Journal Article Clinical cancer research : an official journal of the American Association for Cancer Research · November 2020 PurposeImmunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.Experimental designWe studied KR158 ... Full text Cite

Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging.

Journal Article ACS nano · December 2019 Cancer vaccines initiate antitumor responses in a subset of patients, but the lack of clinically meaningful biomarkers to predict treatment response limits their development. Here, we design multifunctional RNA-loaded magnetic liposomes to initiate potent ... Full text Cite

Massive clonal expansion of medulloblastoma-specific T cells during adoptive cellular therapy.

Journal Article Sci Adv · November 2019 In both human and murine systems, we have developed an adoptive cellular therapy platform against medulloblastoma and glioblastoma that uses dendritic cells pulsed with a tumor RNA transcriptome to expand polyclonal tumor-reactive T cells against a plurali ... Full text Open Access Link to item Cite

Abstract 1194: Adoptive cellular therapy overcomes tumor-induced dysregulation of myelopoiesis

Journal Article Cancer Research · July 1, 2019 AbstractINTRODUCTION: Hematopoietic stem and progenitor cell (HSPC) transfer during adoptive T cell immunotherapy (ACT) prolongs median survival and generates 30% long-term cures for malignant brain tumors. ... Full text Cite

Abstract 4075: Overcoming glioma immunoediting and MHC class I loss during adoptive cellular therapy

Journal Article Cancer Research · July 1, 2019 AbstractIntroduction: Adoptive T cell immunotherapy (ACT) leads to 30% long-term cures of intractable models of malignant glioma. While promising, glioma-bearing hosts succumb to disease for unclear reasons. ... Full text Cite

RNA-Modified T Cells Mediate Effective Delivery of Immunomodulatory Cytokines to Brain Tumors.

Journal Article Molecular therapy : the journal of the American Society of Gene Therapy · April 2019 With the presence of the blood-brain barrier (BBB), successful immunotherapeutic drug delivery to CNS malignancies remains a challenge. Immunomodulatory agents, such as cytokines, can reprogram the intratumoral microenvironment; however, systemic cytokine ... Full text Cite

Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells.

Journal Article Stem cells (Dayton, Ohio) · February 2019 Hematopoietic stem and progenitor cells (HSPCs) are the progenitor cells that can regenerate the entire blood compartment, including the immune system. Recent studies have unearthed considerable immune-modulating potential of these cells. They can migrate ... Full text Cite

Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial.

Journal Article Vaccine · February 2019 BackgroundThe immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysacc ... Full text Cite

Lin-CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade.

Journal Article Nature communications · October 2018 Immune checkpoint blockade using anti-PD-1 monoclonal antibodies has shown considerable promise in the treatment of solid tumors, but brain tumors remain notoriously refractory to treatment. In CNS malignancies that are completely resistant to PD-1 blockad ... Full text Cite

Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma.

Journal Article Clinical cancer research : an official journal of the American Association for Cancer Research · August 2018 Purpose: Adoptive T-cell immunotherapy (ACT) has emerged as a viable therapeutic for peripheral and central nervous system (CNS) tumors. In peripheral cancers, optimal efficacy of ACT is reliant on dendritic cells (DCs) in the tumor microenvironment ... Full text Cite

mRNA-nanoparticles to enhance and track dendritic cell migration.

Journal Article Journal of Clinical Oncology · February 10, 2018 72 Background: Despite aggressive clinical interventions, glioblastoma (GBM) remains almost universally fatal. In a pilot, randomized, and blinded clinical trial, we recently demonstrated that administration of RNA-loaded dendrit ... Full text Cite